Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Korea FDA Moving To Strengthen Pharmacovigilance - APEC Harmonization Center Asia Regulatory Conference

This article was originally published in The Pink Sheet Daily

Executive Summary

A national pharmacovigilance system will integrate an electronic management system in cooperation with the Korea Drug Safety Management Center, local pharmacovigilance centers, public health institutions and government hospitals.

You may also be interested in...

Voices From Emerging Markets Expected At Next ICH Steering Committee - APEC Harmonization Center Regulatory Conference

SEOUL - When ICH was created in 1990, Japan, U.S. and EU were the only participants, but more and more regulatory agencies are adopting variations of ICH guidelines for their own countries. In June, ICH's technical working groups will for the first time be expanded to include regional harmonization initiatives (RHIs), which regulators are calling a "dramatic change" towards global harmonization

Effects Of Korea's New Drug-Pricing System Still Murky

SEOUL - Nearly a year after the South Korean Health Ministry announced new policies aimed at eradicating bribery and promoting more transparent drug pricing, effects of a new drug-pricing system remain unclear, industry watchers say

The REMS Filibuster: FDA Wants Ability To End Post-Approval Talks, Make Final Decision

FDA wants a bigger stick for product-specific Risk Evaluation and Mitigation Strategy negotiations, if for no other reason than to end the talks and make the final decision.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts